420-10-1-.01 Purpose. The purpose of these rules is to provide administrative details and procedures for the care and treatment of newborns identified with phenylketonuria, hypothyroidism, galactosemia, congenital adrenal hyperplasia, hearing loss, hemoglobinopathy, biotinidase deficiency, cystic fibrosis, aminoacidopathies, fatty acid oxidation disorders, organic acidurias and acidemias, critical congenital heart disease and other heritable diseases.

Author: Thomas M. Miller, M.D.


420-10-1-.02 Definitions.

(a) Phenylketonuria - A congenital disease due to a deficit in the metabolism of the amino acid phenylalanine.
Chapter 420-10-1  Health

(b) Hypothyroidism - A deficiency of thyroid gland activity with underproduction of thyroxin or the condition resulting from it.

(c) Hemoglobinopathy - Any hemoglobin phenotype which is other than AA.

(d) Physician of Record - The physician who requests the test.

(e) Galactosemia - An inherited error in the metabolism of galactose.

(f) Congenital adrenal hyperplasia - an inherited error in steroid biosynthesis.

(g) Hearing loss - the total or partial inability to hear sound in one or both ears.

(h) Biotinidase deficiency - inherited deficiency caused by the lack of an enzyme involved in biotin synthesis.

(i) Amino acid disorders - inherited disorders in amino acid metabolism.

(j) Fatty acid oxidation disorders - inherited disorders in fatty acid metabolism.

(k) Organic acid disorders - inherited disorders in organic acid metabolism.

(l) Cystic Fibrosis - inherited disorder caused by a defective protein (cystic fibrosis transmembrane regulator, CFTR) involved in the salt balance of the body.

(m) Critical Congenital Heart Disease (CCHD) - a subset of congenital heart defects characterized by a diminished availability of oxygen to the body tissues that causes severe and life-threatening symptoms and requires intervention within the first days or first year of life.

Authors: Thomas M. Miller, M.D., William J. Callan, Ph.D.


Designation Of Additional Heritable Diseases. The State Board of Health hereby designates the following as a heritable disease subject to testing, reporting and notification requirements herein below specified. Phenylketonuria, hypothyroidism, galactosemia, congenital adrenal hyperplasia, hearing loss, hemoglobinopathy, biotinidase deficiency, cystic fibrosis, aminoacidopathies, fatty acid oxidation disorders, organic acidurias and acidemias, CCHD and other heritable disorders.

Authors: Thomas M. Miller, M.D., William J. Callan, Ph.D.

Reporting And Notification.

(1) The Alabama Department of Public Health shall report all results of phenylketonuria, hypothyroidism, galactosemia, congenital adrenal hyperplasia, hearing loss, hemoglobinopathy, biotinidase deficiency, cystic fibrosis, aminoacidopathies, fatty acid oxidation disorders, organic acidurias and acidemias and other heritable disease testing to the submitting health care provider. Test results on transferred infants may be made available to both the transferring and receiving facilities.

(2) The submitting health care provider shall report all results, including positives, suspected positive results, and unsatisfactory specimens, to the physician of record (the physician indicated on the collection form) of the newborns tested and shall use such forms and follow such guidelines as shall be determined by the State Health Officer. The health care provider shall report the results of any hearing tests performed on the newborns to the Alabama Department of Public Health and shall use such forms and follow such guidelines as shall be determined by the State Health Officer.

(3) The Alabama Department of Public Health may release results of newborn screening tests, including hearing screening results, to any physician registered with the Alabama
Voice Response System under the terms and conditions of the system without a signed release from the parent or guardian.

(4) The submitting health care provider shall screen all newborns in well baby nurseries for CCHD using pulse oximetry and shall use such forms and follow such guidelines as shall be determined by the State Health Officer.

(5) The submitting health care provider shall report the results of any failed pulse oximetry screening results to the Alabama Department of Public Health and shall use such forms and follow such guidelines as shall be determined by the State Health Officer.

Authors: Thomas M. Miller, M.D., William J. Callan, Ph.D.


420-10-1-.05 Counseling And Management.

(a) The Alabama Department of Public Health shall make contact with the physician of record and the parent/guardian of newborns who test positive for phenylketonuria, hypothyroidism, galactosemia, congenital adrenal hyperplasia, hearing loss, hemoglobinopathy, biotinidase deficiency, cystic fibrosis, aminoacidopathies, fatty acid oxidation disorders, organic acidurias and acidemias and other heritable diseases to notify them of positive test results and to ascertain whether or not these newborns are under the care of a private physician. Additionally, the Alabama Department of Public Health shall make contact with the physician of record and the parent/guardian to advise them of the services available through the Alabama Department of Public Health. Newborns who are under the care of a private physician may additionally utilize these same services. The Alabama Department of Public Health may make contact with the family to make their services available or may assist the family in obtaining the services of a private physician. Services include health assessments, treatment, and referrals to tertiary care centers.

(b) The Alabama Department of Public Health shall make contact with the submitting health care provider of newborns with
failed pulse oximetry results to verify that appropriate
screening, referral, and intervention services have been provided
and if needed, may assist in obtaining the services. Services
include health assessments, treatment, and referrals to tertiary
care centers.

Authors: Thomas M. Miller, M.D., William J. Callan, Ph.D.


History: Filed December 21, 1987. Amended: Filed
September 21, 1992; effective October 26, 1992. Amended: Filed
September 18, 2002; effective October 23, 2002. Repealed and New
Amended: Filed December 17, 2007; effective January 21, 2008.

420-10-1-.06 Fees. The Board shall assess and collect newborn
screening fees from hospitals and birthing centers or third party
payors. The newborn screening fee shall be set by the State
Committee of Public Health based on the schedule of laboratory
fees established by Centers for Medicare and Medicaid Services
(CMS) for use by Medicare and Medicaid. The Board shall bill the
Medicaid Agency for Medicaid eligibles.

(1) Hospitals classified as “rural” by CMS or which
have less than 105 beds and are located at least twenty (20)
miles from the nearest acute care facility with obstetrical
capabilities may have newborn screening fees waived for
non-Medicaid eligible patients where there is no third party
payor for such fees. The State Health Officer shall annually
submit a list of hospitals to the Board which are eligible for
waiver of fees.

(2) Additional reasonable and necessary fees may be
charged to other payors by the hospital or physician in
connection with this rule. The State Health Officer may waive
fees deemed uncollectible because of a patient’s inability to
pay.

(3) There shall be only one (1) fee per birth
collected from a hospital by the Board.

Authors: Lloyd Hofer, M.D., William J. Callan, Ph.D.


History: Filed February 19, 1992. Amended: Filed
September 21, 1992; effective October 26, 1992. Repealed and New